Herbalife

(

HLF

) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.4%. By the end of trading, Herbalife fell 58 cents (-1.3%) to $44.85 on light volume. Throughout the day, 2.4 million shares of Herbalife exchanged hands as compared to its average daily volume of four million shares. The stock ranged in price between $44.28-$45.48 after having opened the day at $45.46 as compared to the previous trading day's close of $45.43. Other company's within the Drugs industry that declined today were:

Delcath Systems

(

DCTH

), down 37%,

Rosetta Genomics

(

ROSG

), down 18.7%,

Vermillion

(

VRML

), down 18.4%, and

Prima Biomed Ltd. ADR

(

PBMD

), down 12.6%.

Herbalife Ltd., a network marketing company, sells weight management, nutritional supplement, energy, sports and fitness, and personal care products worldwide. Herbalife has a market cap of $5.26 billion and is part of the

health care

sector. The company has a P/E ratio of 12.9, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 12.1% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Herbalife a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Herbalife as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front,

K-V Pharmaceutical Company

(

KV.A

), up 34.7%,

Complete Genomics

(

GNOM

), up 28.8%,

Medgenics

(

MDGN

), up 25.5%, and

ARCA biopharma

(

ABIO

), up 25.4%, were all gainers within the drugs industry with

Regeneron Pharmaceuticals

(

REGN

) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null